QNASL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Qnasl, and what generic alternatives are available?
Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-three patent family members in thirty-two countries.
The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.
DrugPatentWatch® Generic Entry Outlook for Qnasl
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 24, 2027. This may change due to patent challenges or generic licensing.
There is one tentative approval for the generic drug (beclomethasone dipropionate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for QNASL
| International Patents: | 53 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 65 |
| Patent Applications: | 5,329 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for QNASL |
| What excipients (inactive ingredients) are in QNASL? | QNASL excipients list |
| DailyMed Link: | QNASL at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for QNASL
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for QNASL
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for QNASL
QNASL is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of QNASL is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting QNASL
Nasal spray device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dispensing apparatus with dosage counter
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-002 | Dec 17, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-002 | Dec 17, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for QNASL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-002 | Dec 17, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for QNASL
See the table below for patents covering QNASL around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
